

Effective **July 1, 2021**, the Alberta Biosimilars Initiative will be updated with the following changes that will affect adult members on Alberta government-sponsored drug plans.

Addition of enoxaparin biosimilars – all adult patients on Lovenox must switch by January 10, 2022

1. Update to Alberta Drug Benefit List (ADBL)

On July 1, 2021, two new enoxaparin biosimilar drugs, Inclunox and Redesco were listed on the Alberta Drug Benefit List (ADBL) and will be subject to the Alberta Biosimilar Initiative.

2. Coverage

Effective July 1, 2021, adult patients currently taking the originator drug product, Lovenox, are required to switch to a biosimilar version by January 10, 2022 to maintain coverage for this molecule through their Alberta government-sponsored drug plan. Lovenox will not be eligible for coverage for new enoxaparin starts. All new patient starts for enoxaparin will be covered for the biosimilar.